Cargando…
New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that primarily affects motor neurons in the brain and spinal cord. In the recent past, there have been just two drugs approved for treatment, riluzole and edaravone, which only prolong survival by a few months. However,...
Autores principales: | Jiang, JingSi, Wang, Yan, Deng, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742490/ https://www.ncbi.nlm.nih.gov/pubmed/36518658 http://dx.doi.org/10.3389/fphar.2022.1054006 |
Ejemplares similares
-
Amyotrophic Lateral Sclerosis (ALS) and Adenosine Receptors
por: Sebastião, Ana M., et al.
Publicado: (2018) -
Duality of P2X7 Receptor in Amyotrophic Lateral Sclerosis
por: Volonté, Cinzia, et al.
Publicado: (2020) -
Herbal medicine for amyotrophic lateral sclerosis: A systematic review and meta-analysis
por: Song, Yuebo, et al.
Publicado: (2022) -
Synergistic association of resveratrol and histone deacetylase inhibitors as treatment in amyotrophic lateral sclerosis
por: Parrella, Edoardo, et al.
Publicado: (2022) -
Protein Homeostasis in Amyotrophic Lateral Sclerosis: Therapeutic Opportunities?
por: Webster, Christopher P., et al.
Publicado: (2017)